Experienced in Tongue Cancer

Dr. Donald Sweet

Hematology
1 Salt Creek Ln, 
Hinsdale, IL 
Experienced in Tongue Cancer
1 Salt Creek Ln, 
Hinsdale, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Donald Sweet is a Hematologist in Hinsdale, Illinois. Dr. Sweet is rated as an Experienced provider by MediFind in the treatment of Tongue Cancer. His top areas of expertise are Anal Cancer, Unicentric Castleman Disease (UCD), Castleman Disease, and Multicentric Castleman Disease (MCD).

His clinical research consists of co-authoring 1 peer reviewed article and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in IL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE

Locations

1 Salt Creek Ln, Hinsdale, IL 60521

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Biological
Study Drugs: Bevacizumab, Ipilimumab
Study Phase: Phase 2
The National Myelodysplastic Syndromes Natural History Study
The National Myelodysplastic Syndromes Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2025
Intervention Type: Other
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

1 Total Publications

Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk.
Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk.
Journal: Acta haematologica
Published: April 09, 2021
Similar Doctors
Jochen H. Lorch
Distinguished in Tongue Cancer
Dr. Jochen H. Lorch
Hematology | Oncology
Distinguished in Tongue Cancer
Dr. Jochen H. Lorch
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (16.7 miles away)
866-587-4322
Experience:
31+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jochen Lorch is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Lorch has been practicing medicine for over 31 years and is rated as an Elite provider by MediFind in the treatment of Tongue Cancer. His top areas of expertise are Anaplastic Thyroid Cancer, Thyroid Cancer, Medullary Thyroid Carcinoma, Adenoid Cystic Carcinoma, and Thyroidectomy.

Amar Hamad
Advanced in Tongue Cancer
Dr. Amar Hamad
Hematology | Oncology
Advanced in Tongue Cancer
Dr. Amar Hamad
Hematology | Oncology

Affiliated Oncologists, LLC

10604 Southwest Hwy, 
Chicago Ridge, IL 
 (10.4 miles away)
708-634-4644
Languages Spoken:
English, French
See accepted insurances
Offers Telehealth

Amar Hamad is a Hematologist and an Oncologist in Chicago Ridge, Illinois. Dr. Hamad is rated as a Distinguished provider by MediFind in the treatment of Tongue Cancer. His top areas of expertise are Severe Congenital Neutropenia, Agranulocytosis, Chronic Familial Neutropenia, and Familial Colorectal Cancer.

Advanced in Tongue Cancer
Dr. Everett E. Vokes
Hematology Oncology | Urology | Hematology
Advanced in Tongue Cancer
Dr. Everett E. Vokes
Hematology Oncology | Urology | Hematology

The University Of Chicago

355 E Grand Ave, 
Chicago, IL 
 (16.4 miles away)
888-824-0200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Everett Vokes is a Hematologist Oncology specialist and an Urologist in Chicago, Illinois. Dr. Vokes is rated as an Elite provider by MediFind in the treatment of Tongue Cancer. His top areas of expertise are Small Cell Lung Cancer (SCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Lung Cancer, Gastrostomy, and Bladder Reconstruction. Dr. Vokes is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sweet's expertise for a condition
ConditionClose
    View All 18 Advanced Conditions
    View All 106 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile